APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Distress Syndrome

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

Selected research

Market Outlook & Growth Opportunities

Global Respiratory Distress Syndrome Market Outlook and Growth Opportunities 2026

20 December 2025195 pages

Choose your research edition.

Industry ResearchRespiratory Distress Syndrome Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Distress Syndrome Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Respiratory Distress Syndrome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Distress Syndrome Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Distress Syndrome Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.

North America is the largest consumption place, with a consumption market share nearly 33% . Following North America, China is the second largest consumption place with the consumption market share of 26%.The key manufacturers are Chiesi Farmaceutici, CR-Double Crane, ONY Biotech, AbbVie, Yuhan Corporation, JW Pharmaceuticals, Noargen etc. Top 3 companies occupied about 85% market share.

This report provides an overview of the global Respiratory Distress Syndrome market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Respiratory Distress Syndrome and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Distress Syndrome revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Respiratory Distress Syndrome market.

Respiratory Distress Syndrome Segment by Company

Chiesi Farmaceutici

CR-Double Crane

ONY Biotech

AbbVie

Yuhan Corporation

JW Pharmaceuticals

Noargen

Respiratory Distress Syndrome Segment by Type

Poractant Alfa

Beractant

Calfactant

Others

Respiratory Distress Syndrome Segment by Application

Very Preterm Infants

Moderate to Late Preterm Infants

Others

Respiratory Distress Syndrome Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Respiratory Distress Syndrome status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Respiratory Distress Syndrome key companies, revenue, market share, and recent developments.

3. To split the Respiratory Distress Syndrome breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Respiratory Distress Syndrome market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Respiratory Distress Syndrome significant trends, drivers, influence factors in global and regions.

6. To analyze Respiratory Distress Syndrome competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Distress Syndrome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Distress Syndrome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Distress Syndrome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Distress Syndrome industry.

Chapter 3: Detailed analysis of Respiratory Distress Syndrome company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Respiratory Distress Syndrome in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Respiratory Distress Syndrome in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Respiratory Distress Syndrome Industry Trends Table 2. Respiratory Distress Syndrome Industry Drivers Table 3. Respiratory Distress Syndrome Industry Opportunities and Challenges Table 4. Respiratory Distress Syndrome Industry Restraints Table 5. Global Respiratory Distress Syndrome Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Respiratory Distress Syndrome Revenue Share by Company (2021-2026) Table 7. Global Respiratory Distress Syndrome Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Respiratory Distress Syndrome Key Company Manufacturing Base & Headquarters Table 9. Global Respiratory Distress Syndrome Company, Product Type & Application Table 10. Global Respiratory Distress Syndrome Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Respiratory Distress Syndrome by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Poractant Alfa Table 15. Significant Companies of Beractant Table 16. Significant Companies of Calfactant Table 17. Significant Companies of Others Table 18. Global Respiratory Distress Syndrome Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Respiratory Distress Syndrome Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Respiratory Distress Syndrome Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Respiratory Distress Syndrome Sales Value Share by Type (2021-2026) Table 22. Global Respiratory Distress Syndrome Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Very Preterm Infants Table 24. Significant Companies of Moderate to Late Preterm Infants Table 25. Significant Companies of Others Table 26. Global Respiratory Distress Syndrome Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Respiratory Distress Syndrome Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Respiratory Distress Syndrome Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Respiratory Distress Syndrome Sales Value Share by Application (2021-2026) Table 30. Global Respiratory Distress Syndrome Sales Value Share by Application (2027-2032) Table 31. Global Respiratory Distress Syndrome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Respiratory Distress Syndrome Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Respiratory Distress Syndrome Sales Value Share by Region (2021-2026) Table 34. Global Respiratory Distress Syndrome Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Respiratory Distress Syndrome Sales Value Share by Region (2027-2032) Table 36. Global Respiratory Distress Syndrome Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Respiratory Distress Syndrome Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Respiratory Distress Syndrome Sales Value Market Share by Country (2021-2026) Table 39. Global Respiratory Distress Syndrome Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Respiratory Distress Syndrome Sales Value Market Share by Country (2027-2032) Table 41. Chiesi Farmaceutici Company Information Table 42. Chiesi Farmaceutici Business Overview Table 43. Chiesi Farmaceutici Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio Table 45. Chiesi Farmaceutici Recent Development Table 46. CR-Double Crane Company Information Table 47. CR-Double Crane Business Overview Table 48. CR-Double Crane Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. CR-Double Crane Respiratory Distress Syndrome Product Portfolio Table 50. CR-Double Crane Recent Development Table 51. ONY Biotech Company Information Table 52. ONY Biotech Business Overview Table 53. ONY Biotech Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. ONY Biotech Respiratory Distress Syndrome Product Portfolio Table 55. ONY Biotech Recent Development Table 56. AbbVie Company Information Table 57. AbbVie Business Overview Table 58. AbbVie Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. AbbVie Respiratory Distress Syndrome Product Portfolio Table 60. AbbVie Recent Development Table 61. Yuhan Corporation Company Information Table 62. Yuhan Corporation Business Overview Table 63. Yuhan Corporation Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Yuhan Corporation Respiratory Distress Syndrome Product Portfolio Table 65. Yuhan Corporation Recent Development Table 66. JW Pharmaceuticals Company Information Table 67. JW Pharmaceuticals Business Overview Table 68. JW Pharmaceuticals Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio Table 70. JW Pharmaceuticals Recent Development Table 71. Noargen Company Information Table 72. Noargen Business Overview Table 73. Noargen Respiratory Distress Syndrome Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Noargen Respiratory Distress Syndrome Product Portfolio Table 75. Noargen Recent Development Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Respiratory Distress Syndrome Product Image Figure 2. Global Respiratory Distress Syndrome Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Distress Syndrome Market Size (2021-2032) & (US$ Million) Figure 4. Global Respiratory Distress Syndrome Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Poractant Alfa Image Figure 8. Beractant Image Figure 9. Calfactant Image Figure 10. Others Image Figure 11. Global Respiratory Distress Syndrome Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Respiratory Distress Syndrome Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Respiratory Distress Syndrome Sales Value Share by Type (2021-2032) Figure 14. Very Preterm Infants Image Figure 15. Moderate to Late Preterm Infants Image Figure 16. Others Image Figure 17. Global Respiratory Distress Syndrome Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Respiratory Distress Syndrome Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Respiratory Distress Syndrome Sales Value Share by Application (2021-2032) Figure 20. Global Respiratory Distress Syndrome Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Respiratory Distress Syndrome Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Respiratory Distress Syndrome Sales Value (2021-2032) & (US$ Million) Figure 23. North America Respiratory Distress Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Respiratory Distress Syndrome Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Respiratory Distress Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Respiratory Distress Syndrome Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Respiratory Distress Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Respiratory Distress Syndrome Sales Value (2021-2032) & (US$ Million) Figure 29. South America Respiratory Distress Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Respiratory Distress Syndrome Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Respiratory Distress Syndrome Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Poractant Alfa
  • Beractant
  • Calfactant
  • Others
Applications
  • Very Preterm Infants
  • Moderate to Late Preterm Infants
  • Others
Companies covered
  • Chiesi Farmaceutici
  • CR-Double Crane
  • ONY Biotech
  • AbbVie
  • Yuhan Corporation
  • JW Pharmaceuticals
  • Noargen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Respiratory Distress Syndrome Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Respiratory Distress Syndrome Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Respiratory Distress Syndrome Market Dynamics
  1. 2.1 Respiratory Distress Syndrome Industry Trends
  2. 2.2 Respiratory Distress Syndrome Industry Drivers
  3. 2.3 Respiratory Distress Syndrome Industry Opportunities and Challenges
  4. 2.4 Respiratory Distress Syndrome Industry Restraints
3 Respiratory Distress Syndrome Market by Company
  1. 3.1 Global Respiratory Distress Syndrome Company Revenue Ranking in 2025
  2. 3.2 Global Respiratory Distress Syndrome Revenue by Company (2021-2026)
  3. 3.3 Global Respiratory Distress Syndrome Company Ranking (2024-2026)
  4. 3.4 Global Respiratory Distress Syndrome Company Manufacturing Base and Headquarters
  5. 3.5 Global Respiratory Distress Syndrome Company Product Type and Application
  6. 3.6 Global Respiratory Distress Syndrome Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Respiratory Distress Syndrome Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Respiratory Distress Syndrome Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Respiratory Distress Syndrome Market by Type
  1. 4.1 Respiratory Distress Syndrome Type Introduction
  2. 4.1.1 Poractant Alfa
  3. 4.1.2 Beractant
  4. 4.1.3 Calfactant
  5. 4.1.4 Others
  6. 4.2 Global Respiratory Distress Syndrome Sales Value by Type
  7. 4.2.1 Global Respiratory Distress Syndrome Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Respiratory Distress Syndrome Sales Value by Type (2021-2032)
  9. 4.2.3 Global Respiratory Distress Syndrome Sales Value Share by Type (2021-2032)
5 Respiratory Distress Syndrome Market by Application
  1. 5.1 Respiratory Distress Syndrome Application Introduction
  2. 5.1.1 Very Preterm Infants
  3. 5.1.2 Moderate to Late Preterm Infants
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Distress Syndrome Sales Value by Application
  6. 5.2.1 Global Respiratory Distress Syndrome Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Distress Syndrome Sales Value by Application (2021-2032)
  8. 5.2.3 Global Respiratory Distress Syndrome Sales Value Share by Application (2021-2032)
6 Respiratory Distress Syndrome Regional Value Analysis
  1. 6.1 Global Respiratory Distress Syndrome Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Distress Syndrome Sales Value by Region (2021-2032)
  3. 6.2.1 Global Respiratory Distress Syndrome Sales Value by Region: 2021-2026
  4. 6.2.2 Global Respiratory Distress Syndrome Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Respiratory Distress Syndrome Sales Value (2021-2032)
  7. 6.3.2 North America Respiratory Distress Syndrome Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Respiratory Distress Syndrome Sales Value (2021-2032)
  10. 6.4.2 Europe Respiratory Distress Syndrome Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Respiratory Distress Syndrome Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Respiratory Distress Syndrome Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Respiratory Distress Syndrome Sales Value (2021-2032)
  16. 6.6.2 South America Respiratory Distress Syndrome Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Respiratory Distress Syndrome Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Respiratory Distress Syndrome Sales Value Share by Country, 2025 VS 2032
7 Respiratory Distress Syndrome Country-level Value Analysis
  1. 7.1 Global Respiratory Distress Syndrome Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Respiratory Distress Syndrome Sales Value by Country (2021-2032)
  3. 7.2.1 Global Respiratory Distress Syndrome Sales Value by Country (2021-2026)
  4. 7.2.2 Global Respiratory Distress Syndrome Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Respiratory Distress Syndrome Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Respiratory Distress Syndrome Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Respiratory Distress Syndrome Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chiesi Farmaceutici
  2. 8.1.1 Chiesi Farmaceutici Company Information
  3. 8.1.2 Chiesi Farmaceutici Business Overview
  4. 8.1.3 Chiesi Farmaceutici Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chiesi Farmaceutici Respiratory Distress Syndrome Product Portfolio
  6. 8.1.5 Chiesi Farmaceutici Recent Developments
  7. 8.2 CR-Double Crane
  8. 8.2.1 CR-Double Crane Company Information
  9. 8.2.2 CR-Double Crane Business Overview
  10. 8.2.3 CR-Double Crane Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CR-Double Crane Respiratory Distress Syndrome Product Portfolio
  12. 8.2.5 CR-Double Crane Recent Developments
  13. 8.3 ONY Biotech
  14. 8.3.1 ONY Biotech Company Information
  15. 8.3.2 ONY Biotech Business Overview
  16. 8.3.3 ONY Biotech Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ONY Biotech Respiratory Distress Syndrome Product Portfolio
  18. 8.3.5 ONY Biotech Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Respiratory Distress Syndrome Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Yuhan Corporation
  26. 8.5.1 Yuhan Corporation Company Information
  27. 8.5.2 Yuhan Corporation Business Overview
  28. 8.5.3 Yuhan Corporation Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Yuhan Corporation Respiratory Distress Syndrome Product Portfolio
  30. 8.5.5 Yuhan Corporation Recent Developments
  31. 8.6 JW Pharmaceuticals
  32. 8.6.1 JW Pharmaceuticals Company Information
  33. 8.6.2 JW Pharmaceuticals Business Overview
  34. 8.6.3 JW Pharmaceuticals Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  35. 8.6.4 JW Pharmaceuticals Respiratory Distress Syndrome Product Portfolio
  36. 8.6.5 JW Pharmaceuticals Recent Developments
  37. 8.7 Noargen
  38. 8.7.1 Noargen Company Information
  39. 8.7.2 Noargen Business Overview
  40. 8.7.3 Noargen Respiratory Distress Syndrome Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Noargen Respiratory Distress Syndrome Product Portfolio
  42. 8.7.5 Noargen Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst